TP53 and neoplasm: One of the mechanisms by which ATO treats APL is its ability to bind directly to the cysteine in the zinc finger structure of the fusion protein, mediating the ubiquitinated degradation of PML-RARα.427 Subsequently, a series of reports showed that ATO induced apoptosis in tumor cells carrying TP53 mutations.428–430